Ultragenyx Pharmaceutical(US:RARE) TMX Newsfile·2026-02-16 14:35Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's Phase II results, which lacked a placebo control group [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].